Table 2 Crude and adjusted chance/risk of reproductive outcomes based on modified intention to treat criteriaa

From: Efficacy of clindamycin and LACTIN-V for in vitro fertilization patients with vaginal dysbiosis: a randomised double-blind, placebo-controlled multicentre trial

 

Clindamycin/LACTIN-V (N = 94)

Clindamycin/Placebo (N = 88)

Placebo/Placebo (N = 84)

Both active arms versus Placebo/Placebob

HCG positives

57 (61%)

62% (52–71%)

58 (66%)

65% (56–75%)

50 (60%)

59% (49–69%)

aRR 1.07 (0.87–1.32)

Clinical pregnancy week 7–9

39 (41%)

42% (32–52%)

41 (47%)

46% (36–56%)

38 (45%)

45% (35–56%)

aRR 0.98 (0.74–1.29)

Ongoing pregnancy week 10–12

38 (40%)

41% (31–51%)

40 (45%)

45% (35–55%)

37 (44%)

44% (34–54%)

aRR 0.97 (0.73–1.29)

Early pregnancy loss

19 (33%)

34% (21–46%)

18 (31%)

31% (19–43%)

13 (26%)

26% (14–38%)

aRR 1.24 (0.73–2.11)

Live birth

37 (39%)

40% (30–50%)

40 (45%)

45% (35–55%)

34 (40%)

40% (30–51%)

aRR 1.05 (0.77–1.42)

Gemelli

0

0

0

N/A

Preterm birth <37weeks

4 (4%)

2 (2%)

4 (5%)

c

Median birth weight (IQR)

3580 grams

(2930–3935)

3488 grams

(3140–3665)

3813 grams (3220–4035)

c

  1. Unless otherwise indicated, top line is the crude number of outcome N (%) and were possible below the adjusted proportion and 95.1% confidence intervals adjusted for female age and embryo quality as based on the statistical model. aRR adjusted risk ratio, IQR Interquartile range.
  2. aAll patients with an embryo transfer less than 63 days from the active treatment start to cycle day 1 in the same menstrual cycle as the embryo transfer.
  3. bAverage effect of the two active arms compared to placebo.
  4. cNot statistically different between groups.